OCGN Quote, Financials, Valuation and Earnings

CorMedix, Inc. has a net margin of -1144.46% compared to Ocugen, Inc.'s net margin of 49.9%. Ocugen, Inc.'s return on equity of -345.08% beat CorMedix, Inc.'s return on equity of 95.25%.

Ocugen, Inc. has a consensus price target of $9.00, signalling upside risk potential of 432.54%. On the other hand CorMedix, Inc. has an analysts' consensus of $16.86 which suggests that it could grow by 148.63%. Given that Ocugen, Inc. has higher upside potential than CorMedix, Inc., analysts believe Ocugen, Inc. is more attractive than CorMedix, Inc..

Ocugen, Inc. has a beta of 3.501, which suggesting that the stock is 250.127% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.358, suggesting its more volatile than the S&P 500 by 35.753%.

Ocugen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Ocugen, Inc. quarterly revenues are $1.8M, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Ocugen, Inc.'s net income of -$20.1M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Ocugen, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen, Inc. is 92.76x versus 2.28x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

MannKind Corp. has a net margin of -1144.46% compared to Ocugen, Inc.'s net margin of 9.72%. Ocugen, Inc.'s return on equity of -345.08% beat MannKind Corp.'s return on equity of --.

Ocugen, Inc. has a consensus price target of $9.00, signalling upside risk potential of 432.54%. On the other hand MannKind Corp. has an analysts' consensus of $9.61 which suggests that it could grow by 84.47%. Given that Ocugen, Inc. has higher upside potential than MannKind Corp., analysts believe Ocugen, Inc. is more attractive than MannKind Corp..

Ocugen, Inc. has a beta of 3.501, which suggesting that the stock is 250.127% more volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.815, suggesting its less volatile than the S&P 500 by 18.55%.

Ocugen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.

Ocugen, Inc. quarterly revenues are $1.8M, which are smaller than MannKind Corp. quarterly revenues of $82.1M. Ocugen, Inc.'s net income of -$20.1M is lower than MannKind Corp.'s net income of $8M. Notably, Ocugen, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 55.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen, Inc. is 92.76x versus 5.12x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -1144.46% compared to Ocugen, Inc.'s net margin of 21.32%. Ocugen, Inc.'s return on equity of -345.08% beat Pfizer Inc.'s return on equity of 10.84%.

Ocugen, Inc. has a consensus price target of $9.00, signalling upside risk potential of 432.54%. On the other hand Pfizer Inc. has an analysts' consensus of $28.66 which suggests that it could grow by 11.72%. Given that Ocugen, Inc. has higher upside potential than Pfizer Inc., analysts believe Ocugen, Inc. is more attractive than Pfizer Inc..

Ocugen, Inc. has a beta of 3.501, which suggesting that the stock is 250.127% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Ocugen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.71% to investors and pays a quarterly dividend of $0.43 per share. Ocugen, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Ocugen, Inc. quarterly revenues are $1.8M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Ocugen, Inc.'s net income of -$20.1M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Ocugen, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen, Inc. is 92.76x versus 2.33x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of -1144.46% compared to Ocugen, Inc.'s net margin of 34.76%. Ocugen, Inc.'s return on equity of -345.08% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Ocugen, Inc. has a consensus price target of $9.00, signalling upside risk potential of 432.54%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $500.40 which suggests that it could grow by 13.38%. Given that Ocugen, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Ocugen, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Ocugen, Inc. has a beta of 3.501, which suggesting that the stock is 250.127% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.310, suggesting its less volatile than the S&P 500 by 69.005%.

Ocugen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ocugen, Inc. quarterly revenues are $1.8M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Ocugen, Inc.'s net income of -$20.1M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Ocugen, Inc.'s price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 31.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen, Inc. is 92.76x versus 9.75x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.